StockNews.com Begins Coverage on Mesoblast (NASDAQ:MESO)

StockNews.com started coverage on shares of Mesoblast (NASDAQ:MESO – Get Rating) in a report issued on Thursday. The firm set a “sell” rating on the stock.

Separately, Zacks Investment Research lowered shares of Mesoblast from a “hold” rating to a “sell” rating in a research report on Thursday, May 19th. Three analysts have rated the stock with a sell rating, one has given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, Mesoblast currently has a consensus rating of “Hold” and an average price target of $9.83.

Shares of NASDAQ:MESO opened at $3.48 on Thursday. Mesoblast has a 12 month low of $3.23 and a 12 month high of $8.85. The company has a market cap of $452.72 million, a price-to-earnings ratio of -4.58 and a beta of 3.05. The company has a current ratio of 1.88, a quick ratio of 1.88 and a debt-to-equity ratio of 0.16. The company has a 50-day moving average price of $3.98 and a 200 day moving average price of $4.55.

Mesoblast (NASDAQ:MESO – Get Rating) last released its quarterly earnings results on Thursday, February 24th. The company reported ($0.20) earnings per share (EPS) for the quarter. The firm had revenue of $2.38 million during the quarter, compared to analysts’ expectations of $2.70 million. Mesoblast had a negative return on equity of 17.07% and a negative net margin of 982.76%. As a group, equities analysts forecast that Mesoblast will post -0.49 EPS for the current year.

A number of institutional investors have recently bought and sold shares of the business. JustInvest LLC acquired a new stake in Mesoblast during the 4th quarter worth approximately $53,000. Summit X LLC purchased a new position in Mesoblast during the first quarter worth $60,000. Tobias Financial Advisors Inc. acquired a new position in Mesoblast in the 1st quarter valued at about $84,000. Sio Capital Management LLC purchased a new position in shares of Mesoblast during the fourth quarter valued at approximately $128,000. Finally, Lattice Capital Management LLC purchased a new stake in shares of Mesoblast in the fourth quarter valued at $144,000. Institutional investors own 2.72% of the company’s stock.

About Mesoblast (Get Rating)

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases.

Further Reading